Apogee Therapeutics, Inc. 8-K

What Happened

• Apogee Therapeutics, Inc. announced an underwriting agreement dated March 24, 2026, to sell 5,000,000 shares of common stock at $70.00 per share and granted the underwriters a 30-day option for an additional 750,000 shares. The underwriters exercised the full option on March 25, 2026. After underwriting discounts, commissions and estimated offering expenses, net proceeds are expected to be approximately $377.4 million. The offering was made from a shelf registration (File No. 333-281503) and was expected to close on March 26, 2026.

Key Details

• Shares offered: 5,000,000 primary shares; Option exercised: 750,000 additional shares (total 5,750,000).
• Public offering price: $70.00 per share.
• Net proceeds (expected): approximately $377.4 million after fees and expenses.
• Underwriters: Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Inc., and Guggenheim Securities, LLC (representatives).
• Legal: Opinion of Gibson, Dunn & Crutcher LLP relating to validity of the issuance filed as Exhibit 5.1.
• Shelf registration effective date: August 12, 2024; offering prospectus supplement filed March 24–25, 2026.

Why It Matters

• This transaction increases Apogee’s cash resources by roughly $377 million (net), which affects the company’s liquidity and ability to fund operations.
• The issuance of 5,750,000 new shares will increase the total shares outstanding, resulting in dilution for existing shareholders.
• Investors should note the offering terms, underwriters involved, and the expected closing date (March 26, 2026) when assessing short-term share supply and company financing position.